Medicine. The need for a global HIV vaccine enterprise.

Published

Journal Article

A new collaborative model of research is needed to increase resources, to prioritize the R (ii) to increase the pace, reduce the overlap, and more systematically explore the elements of and delivery systems for vaccines; (iii) to use common standards for the prompt comparative testing of vaccine candidates; (iv) to expand resources for manufacturing vaccine candidates to speed their use in human trials; and (v) to increase the capacity for international clinical trials and to focus this effort toward quickly measuring the effectiveness of vaccine protection as prototype vaccine candidates are identified.

Full Text

Duke Authors

Cited Authors

  • Klausner, RD; Fauci, AS; Corey, L; Nabel, GJ; Gayle, H; Berkley, S; Haynes, BF; Baltimore, D; Collins, C; Douglas, RG; Esparza, J; Francis, DP; Ganguly, NK; Gerberding, JL; Johnston, MI; Kazatchkine, MD; McMichael, AJ; Makgoba, MW; Pantaleo, G; Piot, P; Shao, Y; Tramont, E; Varmus, H; Wasserheit, JN

Published Date

  • June 2003

Published In

Volume / Issue

  • 300 / 5628

Start / End Page

  • 2036 - 2039

PubMed ID

  • 12829768

Pubmed Central ID

  • 12829768

Electronic International Standard Serial Number (EISSN)

  • 1095-9203

International Standard Serial Number (ISSN)

  • 0036-8075

Digital Object Identifier (DOI)

  • 10.1126/science.1086916

Language

  • eng